Liver Stiffness Better Reflects Cumulative Hepatic Injury Than Iron Concentration in Thalassemia

Evolving Strategies for Hepatic Monitoring in Thalassemia

The clinical management of transfusion-dependent thalassemia has transitioned from a focus on acute survival to the long-term mitigation of multi-organ complications. While iron chelation therapy has significantly improved life expectancy, chronic iron overload remains a primary driver of progressive liver fibrosis and eventual cirrhosis [1, 2]. This risk is frequently compounded by historical viral hepatitis and emerging metabolic dysfunction-associated steatotic liver disease, which act synergistically to promote hepatic injury [3]. Although magnetic resonance imaging has become the standard for quantifying liver iron concentration (a non-invasive measurement of the total iron stored within hepatic tissue), these measurements provide a temporal snapshot that may not fully reflect the cumulative architectural damage caused by sustained oxidative stress [2, 4]. Furthermore, the complex interplay between iron-related toxicity and systemic inflammation underscores the need for non-invasive tools that can more accurately stage fibrosis to guide therapeutic intensity [5, 6]. A recent study now provides critical evidence on how elastography-based stiffness measurements can refine the clinical assessment of these high-risk patients.

Elastography and Iron Quantification in a Multicenter Cohort

To evaluate the relationship between iron burden and structural liver damage, researchers conducted a retrospective analysis of 831 patients with transfusion-dependent thalassemia who were monitored between 2010 and 2019. These patients were identified through the Webthal computerized medical record system (a specialized digital registry for tracking longitudinal data in patients with hemoglobin disorders) at four Italian reference centers. From this larger registry, the investigators selected a specific sub-group of 165 patients who had undergone both liver stiffness measurement and liver iron concentration assessment within the same calendar year. To ensure the clarity of the data, the study excluded individuals with a diagnosis of hepatocellular carcinoma, HIV, or Hepatitis B Virus infection. Furthermore, the cohort was confirmed to have no intrahepatic mass-like extramedullary hematopoiesis (the formation of blood cells outside the bone marrow, which can manifest as liver masses in patients with chronic anemia and confound stiffness readings). The study population had a median age of 38.5 years (interquartile range 30.5 to 43.0) and was nearly evenly split by sex, with 51% being male. Pediatric patients under the age of 12 years accounted for 2.4% of the cohort, a group for whom international validation of elastography is still emerging. Clinical comorbidities were prevalent, as 61% of the patients (101 individuals) had undergone a splenectomy and 14% (23 individuals) were diagnosed with diabetes. Regarding viral history, 100 patients (61%) were positive for Hepatitis C Virus antibodies. For these patients, the researchers utilized clinical evaluations conducted after the completion of treatment with direct-acting antiviral drugs to minimize the confounding effects of active viral replication on liver measurements. Liver stiffness was quantified using transient elastography (FibroScan), a non-invasive ultrasound-based technology that measures the speed of shear waves through the liver to assess tissue density, following the clinical guidelines established by the European Association for the Study of the Liver. In accordance with these standards, the researchers utilized a cutoff of 8 kPa to define advanced liver fibrosis, also known as bridging fibrosis. This threshold was selected because values below 8 kPa are clinically associated with a very low probability of advanced histological disease. By applying this standardized metric alongside quantitative iron assessments, the study aimed to determine whether current iron levels or cumulative tissue damage better represents the overall hepatic burden in the modern era of chelation therapy.

Discordance Between Fibrosis Markers and Iron Overload

The analysis of the 165-patient cohort revealed a median liver stiffness measurement of 5.2 kPa (Q1–Q3: 4.3 to 6.3), a value generally indicative of mild to no fibrosis. When applying the clinical threshold for advanced disease, 151 patients (91.5%) were classified as having no advanced liver fibrosis, defined by a liver stiffness measurement below 8 kPa. Within this subgroup, the median stiffness was 5.1 kPa (Q1–Q3: 4.2 to 5.9). Despite these relatively low stiffness readings, the biochemical markers of iron burden remained elevated across the population. The median serum ferritin level was 1207 ng/mL (Q1–Q3: 467 to 2522), and the median liver iron concentration was 3.6 mg/g dry weight (Q1–Q3: 1.9 to 8.3). These figures suggest that while many patients maintain stable liver architecture, they continue to harbor significant systemic and hepatic iron stores. The distribution of liver iron concentration further illustrated the variability of iron control in this population. While 76 patients (46%) showed no current iron overload with a concentration below 3 mg/g dry weight, the remainder of the cohort exhibited varying degrees of accumulation: 38 patients (23%) had mild overload (3 to less than 7 mg/g), 34 (21%) had moderate overload (7 to less than 15 mg/g), and 17 (10%) remained in the severe overload category with concentrations of 15 mg/g or higher. Notably, among the 151 patients with liver stiffness below 8 kPa, a substantial proportion still exhibited significant iron deposits, including 14 patients (9.3%) with severe, 34 (23%) with moderate, and 33 (22%) with mild iron overload. Only 70 patients (46.4%) in this low-stiffness group had no iron overload, highlighting that low liver stiffness does not necessarily preclude high iron concentration. Clinical assessment of liver health through biochemical testing showed that abnormal liver function tests were present in 20 patients (12%). Univariate analyses demonstrated that liver stiffness measurements were significantly associated with several key biochemical parameters, including aspartate aminotransferase (p < 0.001), alanine aminotransferase (p = 0.005), and gamma GT (p = 0.022). In contrast, the researchers observed non-significant negative associations between liver stiffness and total bilirubin (p = 0.2) or indirect bilirubin (p = 0.15). Furthermore, several clinical factors showed positive but non-significant associations with increased liver stiffness, including male sex (p = 0.08), liver iron concentration (p = 0.09), Hepatitis C Virus status (p = 0.12), prior splenectomy (p = 0.14), and hypoparathyroidism (p = 0.08). These findings suggest that while liver stiffness correlates strongly with active enzymatic markers of hepatocellular injury, its relationship with current iron concentration is less direct, potentially reflecting the cumulative rather than acute impact of iron-mediated damage.

The Impact of Viral History and Splenectomy on Liver Architecture

The study highlighted a distinct discordance between current iron stores and structural liver damage in patients with a history of Hepatitis C Virus infection. Among the 100 patients who were Hepatitis C Virus antibody positive, the median liver iron concentration was significantly lower at 2.8 mg/g dry weight compared to 6.5 mg/g dry weight in those who were antibody negative (p < 0.001). Despite having less hepatic iron, these Hepatitis C Virus positive patients exhibited higher median liver stiffness measurements of 5.5 kPa versus 5.1 kPa in the negative group (p = 0.1). When the researchers adjusted for age and sex, the statistical association between liver stiffness and iron concentration remained significant only in patients who were negative for Hepatitis C Virus antibodies. This suggests that in patients with a history of viral exposure, the liver stiffness measurement reflects the cumulative architectural damage from past infection rather than current iron levels. Further analysis of the high-risk subgroup revealed that 14 patients (8.5%) had advanced liver stiffness, defined as a measurement of 8 kPa or higher, with a median value of 10.35 kPa (Q1, Q3: 8.8 to 12.3). Within this specific group, 10 patients (71%) were positive for Hepatitis C Virus antibodies, and the median liver iron concentration was 4.7 mg/g dry weight (Q1, Q3: 1.7 to 6.5). The distribution of iron overload in these 14 patients was highly variable: 3 patients (21%) had severe iron overload, 5 (36%) had mild overload, and 6 (43%) had no iron overload at all. Crucially, the researchers found no significant association between liver stiffness and iron concentration in these patients with advanced fibrosis. Because these individuals had been on a stable dose of oral iron chelation therapy for at least six months prior to the analysis, the findings suggest that the observed stiffness was not a result of acute, intensive chelation but rather a reflection of chronic, irreversible hepatic injury. The clinical implications of these findings are underscored by the unique pathophysiology of transfusion-dependent thalassemia, particularly regarding the role of the spleen. While splenectomy is often associated with reduced fibrosis in other liver diseases, it showed a positive association with increased liver stiffness in this cohort (p = 0.14). This may be due to the loss of the spleen's role as a scavenger for non-transferrin-bound iron species (toxic iron molecules not bound to transport proteins like transferrin), which then increases the exposure of the liver to oxidative stress. Ultimately, the data indicate that liver stiffness measurements of 8 kPa or higher better reflect the total chronic hepatic disease burden than liver iron concentration, which provides only a snapshot of current iron status. For the clinician, this means that even when iron levels are well-controlled, elevated stiffness should prompt an investigation into other liver-toxic factors such as metabolic disorders, alcohol use, or the long-term sequelae of viral hepatitis.

References

1. Crawford DH, Ramm GA, Bridle KR, Nicoll A, Delatycki MB, Olynyk JK. Clinical practice guidelines on hemochromatosis: Asian Pacific Association for the Study of the Liver. Hepatology International. 2023. doi:10.1007/s12072-023-10510-3

2. Feng Q, Yi J, Li T, Liang B, Xu F, Peng P. Narrative review of magnetic resonance imaging in quantifying liver iron load. Frontiers in Medicine. 2024. doi:10.3389/fmed.2024.1321513

3. Fragkou N, Vlachaki E, Goulis I, Sinakos E. Liver disease in patients with transfusion-dependent β-thalassemia: The emerging role of metabolism dysfunction-associated steatotic liver disease. World Journal of Hepatology. 2024. doi:10.4254/wjh.v16.i5.671

4. Obrzut M, Atamaniuk V, Glaser KJ, et al. Value of liver iron concentration in healthy volunteers assessed by MRI. Scientific Reports. 2020. doi:10.1038/s41598-020-74968-z

5. Chuljerm H, Maneekesorn S, Thorup GL, Nantakool S, Charoenkwan P, Rerkasem K. The Relevance of Endothelial Dysfunction Biomarkers in Thalassemia Patients and Healthy Individuals: A Systematic Review and Meta-Analysis. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26083842

6. Özkaramehmet S, Andreou S, Yiangou K, et al. Evaluation of Five Plasma miRNAs as Biomarkers for Minimally Invasive Staging of Liver Fibrosis in β-Thalassaemia Patients. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26199543